Christopher Von Seggern stepped down as Chief Commercial Officer of Xenon Pharmaceuticals Inc. and departed from the company. In connection with his departure ...

Assenagon Asset Management S.A. raised its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 12.4% during the 4th quarter, HoldingsChannel reports. The fund owned 238,522 shares of ...

For the mountaineers, climbing the peaks of Mount Everest is the piece de resistance of their careers. What a lot of people don't realize is that accomplishing ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a $3 billion market cap pharmaceutical company specializing in the development of therapeutic drugs, announced today the departure of its Chief Commercial ...

A group of mountaineers plan to travel from Heathrow to the summit of Mount Everest and back in just seven days - a feat ...

Xenon has promising Phase 2 data for MDD treatment, robust financials, and a potential in niche markets, despite premium ...

Recently, the Financial Times released an article featuring a climbing company whose goal is to offer their clients the use of xenon gas to make acclimatizing safer and to cut down the length of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The next Alzheimer’s treatment could come from an unexpected place. In new research released this week, scientists have found ...